Where evolutionary meets revolutionary to improve human health

Who we are

Peel Therapeutics is on an expedition to unlock nature’s secrets and overcome life-threatening conditions. These evolutionary outliers rarely make their way to patients, and we are determined to change that.

We are an evolutionary-inspired, clinical-stage biotech company developing medicines to transform patients’ lives. Peel (the Hebrew word for “elephant”) launched with our focus on cancer-fighting proteins in elephants and we quickly recognized the power of using evolution’s solutions to treat and prevent disease. In addition to developing elephant p53 (EP53) nanoparticles for the treatment of cancer, our team is advancing additional therapies derived from nature’s superabilities to treat cancer and immune diseases.

Our Approach

Life science R&D has produced countless new therapies with positive health outcomes, but it cannot compare to ages of evolutionary history. With deep knowledge of evolutionary biology and comparative genomics, we use Darwin.AI™ to seek out novel targets and molecules in nature that have exceeded what we thought was biologically possible. We then apply our drug development expertise to rapidly translate this into evolutionary medicines and advance our therapeutic pipeline to treat a spectrum of devastating conditions, including cancer and immune diseases. Our therapy’s efficacy is derived from its validation in 100 million years of evolutionary development — maximizing impact while minimizing side-effects.

“Peel” is the Hebrew word for elephant.

Elephants are naturally cancer-resistant creatures.

The Chinese Happy Tree has been used to treat many ailments including:

Cancer
Colds
Liver Disorders
Digestion Issues

About 25% of the drugs prescribed worldwide are derived from plants.

Our Mission

Peel Therapeutics’ mission is to unlock evolutionary biology to improve patient lives.

mission-vision_PHOTO_2_Nature_Crystal_Ball

Our Vision

Peel Therapeutics aims to develop safe and highly effective medicines that transform patient care.

Our Leadership

Our multidisciplinary team across the US and Israel offers a unique blend of scientific and medical expertise, enthusiasm and curiosity. We hail from all corners of industry, academia, and clinical medicine, and the patients we serve are the driving force behind the work we do every day.

Leadership Board of Directors Board of Advisors

Joshua Schiffman, MD

February 10, 2023

CEO and Co-Founder

Adi Dror, PhD

June 24, 2022

Director of Protein Development

Nitzan Krinsky, PhD, MBA

June 24, 2022

Director of Formulation and Assay Development

Mor Goldfeder, PhD, MBA

June 24, 2022

VP of Technology & Early Development
Managing Director of Peel Israel

Trent Fowler, MBA

June 24, 2022

VP of Operations

Aleah Caulin, PhD

June 24, 2022

VP of Nonclinical

Debra Vallner, PhD, MBA

June 24, 2022

SVP Development Operations

Jim Levison, MBA

June 24, 2022

CFO

Robert Forrester

December 11, 2023

Chairman

Carin Canale-Theakston

February 13, 2023

Director

Ryan Watts, Ph.D.

February 10, 2023

Director

Mary Tolan, MBA

June 24, 2022

Director

John Warnock, PhD

June 24, 2022

Director in Memoriam

Avi Schroeder, PhD

June 24, 2022

Co-Founder and Director

Joshua Schiffman, MD

June 24, 2022

CEO, Co-Founder, Director

Christopher A. Jones, PhD

July 18, 2022

Advisor

Matthew J. LaMarche, PhD

June 24, 2022

Advisor

Yosef Zweibach

June 24, 2022

Advisor

Jay Sullivan, JD

June 24, 2022

Advisor

Adam Cutler

June 24, 2022

Advisor

Mark Blumenkranz MD, MMS

June 24, 2022

Advisor

Sam Blackman, MD, PhD

June 24, 2022

Advisor

Peel
Perspective

The potential of Peel’s pipeline fueled by the company’s evolutionary insight is enormous. Peel scientists have identified exciting therapeutic targets, have developed cutting-edge delivery technology, and have demonstrated strong preclinical success – with their first clinical trial now enrolling patients. Peel’s approach avoids the common missteps in pharma drug pipelines by taking advantage of “nature’s R&D pipeline” with hundreds of millions of years of evolutionary success. Their first three assets scratch the surface of the opportunities for Peel and I’m excited by the scale at which Peel can positively impact patient lives.”

Willard Dere, MDFormer SVP and CMO of Amgen, Inc.
Peel Therapeutics Past Board Member

I have been an enthusiastic investor in Peel Therapeutics since the beginning. Dr. Schiffman and his remarkable team have insight and talent that learns from the lessons of evolution, medicine and chemistry. They translate that knowledge into treatments and defenses for human weaknesses and disease. They also have a remarkable judgement about timelines of development that will optimize the return on investment into the Company.”

John Warnock, PhDCo-founder of Adobe Systems, Inc.
Peel Therapeutics Director in Memoriam

I am proud to be an investor and board member of Peel Therapeutics, a company I believe will have disproportionate impact in the realm of curing disease and restoring health. The Company is advancing new breakthroughs at the intersection of evolutionary science and technology to bring nature’s insights to new therapeutic treatments. Its visionary leadership from CEO and Co-Founder Dr. Joshua Schiffman and Co-Founder Avi Schroeder is leading multi-disciplinary teams in the US and Israel who are creative, rigorous and tenacious in advancing the work and the pathway to impact.”

Mary TolanFounder of Chicago Pacific Founders
Peel Therapeutics Board Member

Where evolutionary meets revolutionary to improve human health

Who we are

Our Approach

“Peel” is the Hebrew word for elephant.

Elephants are naturally cancer-resistant creatures.

The Chinese Happy Tree has been used to treat many ailments including:

About 25% of the drugs prescribed worldwide are derived from plants.

Our Mission

Our Vision

Our Leadership

Peel Perspective

Peel
Perspective